Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $102,000.

  • Zenas BioPharma's Change in Accured Expenses rose 537.50% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 27.42%. This contributed to the annual value of $22.1 million for FY2024, which is 720.15% up from last year.
  • Per Zenas BioPharma's latest filing, its Change in Accured Expenses stood at $102,000 for Q3 2025, which was down 99.37% from $16.3 million recorded in Q2 2025.
  • Zenas BioPharma's Change in Accured Expenses' 5-year high stood at $16.3 million during Q2 2025, with a 5-year trough of -$11.2 million in Q1 2025.
  • For the 3-year period, Zenas BioPharma's Change in Accured Expenses averaged around $3.8 million, with its median value being $2.4 million (2023).
  • The largest annual percentage gain for Zenas BioPharma's Change in Accured Expenses in the last 5 years was 537.50% (2025), contrasted with its biggest fall of 844.33% (2025).
  • Quarterly analysis of 3 years shows Zenas BioPharma's Change in Accured Expenses stood at $3.2 million in 2023, then surged by 267.00% to $11.9 million in 2024, then skyrocketed by 537.50% to $102,000 in 2025.
  • Its Change in Accured Expenses was $102,000 in Q3 2025, compared to $16.3 million in Q2 2025 and -$11.2 million in Q1 2025.